Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + tepotinib
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cetuximab + tepotinib is an investigational combination therapy consisting of two targeted agents used in oncology. Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting its signaling and thereby blocking tumor cell proliferation and survival. Tepotinib is a small molecule inhibitor of the mesenchymal-epithelial transition factor (MET) receptor tyrosine kinase, which can drive cancer progression when amplified or overexpressed. This combination has been studied primarily in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) who have developed resistance to anti-EGFR antibody therapy due to MET amplification. The rationale for combining these agents is to overcome acquired resistance mechanisms by simultaneously targeting EGFR and MET pathways[1][4][5].
- Brand names
- tepotinibcetuximab
- Other names
- tepotinibcetuximab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on cetuximab + tepotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + tepotinib.